Clorox (CLX) PT Raised to $146.00

Clorox (NYSE:CLX) had its target price hoisted by investment analysts at Wells Fargo & Co from $130.00 to $146.00 in a research note issued on Thursday. The firm currently has a “market perform” rating on the stock. Wells Fargo & Co’s price target points to a potential upside of 1.79% from the company’s previous close.

CLX has been the topic of a number of other research reports. Jefferies Group reaffirmed a “hold” rating and set a $132.00 price target on shares of Clorox in a report on Wednesday, November 1st. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Morgan Stanley dropped their target price on Clorox from $138.00 to $128.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Royal Bank of Canada reissued a “hold” rating and set a $115.00 target price on shares of Clorox in a report on Sunday, October 8th. Finally, BMO Capital Markets reissued a “buy” rating and set a $150.00 target price on shares of Clorox in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $132.05.

Shares of Clorox (NYSE CLX) opened at $143.43 on Thursday. The firm has a market capitalization of $18,680.00, a P/E ratio of 26.32, a PEG ratio of 3.94 and a beta of 0.42. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. Clorox has a twelve month low of $118.41 and a twelve month high of $150.40.

Clorox (NYSE:CLX) last released its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.05. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.48 billion. Clorox had a return on equity of 161.59% and a net margin of 11.84%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.36 earnings per share. sell-side analysts forecast that Clorox will post 5.6 EPS for the current year.

In other Clorox news, SVP Matthew T. Laszlo sold 20,051 shares of Clorox stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total value of $2,615,853.46. Following the transaction, the senior vice president now owns 10,896 shares in the company, valued at $1,421,492.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael R. Costello sold 10,574 shares of Clorox stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the completion of the transaction, the senior vice president now owns 34,867 shares in the company, valued at approximately $4,742,260.67. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Sun Life Financial INC grew its position in Clorox by 10,344.4% in the second quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after buying an additional 931 shares during the last quarter. Acrospire Investment Management LLC acquired a new position in Clorox in the second quarter worth approximately $133,000. Salem Investment Counselors Inc. grew its position in Clorox by 2.5% in the second quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after buying an additional 31 shares during the last quarter. Phocas Financial Corp. purchased a new position in Clorox during the 2nd quarter worth approximately $167,000. Finally, Jacobi Capital Management LLC grew its position in Clorox by 0.3% during the 2nd quarter. Jacobi Capital Management LLC now owns 1,286 shares of the company’s stock worth $172,000 after purchasing an additional 4 shares in the last quarter. Hedge funds and other institutional investors own 73.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Clorox (CLX) PT Raised to $146.00” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/04/clorox-clx-pt-raised-to-146-00.html.

Clorox Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Leave a Reply